Clinical trials
Urinary Bladder, Overactive trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 24 |
| Terminated | 3 |
| Not yet recruiting | 2 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Astellas Pharma Inc | 7 |
| Pfizer | 4 |
| Astellas Pharma Europe B.V. | 3 |
| Allergan | 2 |
| Astellas Pharma Europe Ltd. | 2 |
| Ipsen | 2 |
| Università degli Studi dell'Insubria | 2 |
| Astellas Pharma Global Development, Inc. | 1 |
| IRCCS San Raffaele | 1 |
| MedtronicNeuro | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Urinary Bladder, Overactive | 30 |
| Urinary Incontinence | 11 |
| Urinary Incontinence, Urge | 5 |
| Urinary Bladder Diseases | 3 |
| Urologic Diseases | 3 |
| Nocturia | 2 |
| Lower Urinary Tract Symptoms | 1 |
| Prostatic Hyperplasia | 1 |
| Signs and Symptoms | 1 |
| Urinary Bladder, Underactive | 1 |
Trials
Showing 76 to 30 of 30. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.